EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing

Nicole E Omecene iD, Nicole Wilcox, Alexandra L Cox, Pearl Ham, Ryan Ong, Andrew T Barber, Kristin M Zimmerman

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Nicole E Omecene und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Proton Pump Inhibitors, Deprescriptions, Gastroesophageal Reflux. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of proton‐pump inhibitors (PPIs) is common among people with cystic fibrosis (pwCF) both for the management of suspected GERD, as well as pancreatic enzyme replacement therapy augmentation. Despite their use, limited data exist to demonstrate a clinically significant impact of PPIs on key endpoints in pwCF. Furthermore, the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy may modify the need for use. These notions, coupled with the potential for adverse outcomes associated with long‐term PPI use in pwCF, should facilitate re‐evaluation of long‐term PPI use in pwCF and promote potential deprescribing. Despite limited data on PPI deprescribing in pwCF, it intuitively mirrors the existing guidance in adults in the general population, but with added consideration given to tapering strategy, and monitoring for CF‐specific outcomes such as nutritional and respiratory status. The development of a monitoring and re‐initiation plan is key to reducing deprescribing inertia. This review aims to summarize the evidence that details the concern for long‐term use of PPIs and provide CF clinicians with rationale and guidance on how to approach deprescribing in their practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisProton Pump InhibitorsDeprescriptionsGastroesophageal RefluxHumans

Stichwörter der Autor:innen

adverse drug reactionexocrine pancreatic insufficiencygastroesophageal refluxpolypharmacy

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.
  • Department of Pharmacy, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Pharmacy, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA.
  • Division of Pediatric Pulmonary and Sleep Medicine, Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA.

ORCID-Profile: Nicole E Omecene

Zitieren

APA

Omecene, N. E., Wilcox, N., Cox, A. L., Ham, P., Ong, R., Barber, A. T., & Zimmerman, K. M. (2024). A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27229

Vancouver

Omecene NE, Wilcox N, Cox AL, Ham P, Ong R, Barber AT, et al. A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27229

BibTeX
@article{Omecene2024,
  author = {Omecene, Nicole E and Wilcox, Nicole and Cox, Alexandra L and Ham, Pearl and Ong, Ryan and Barber, Andrew T and Zimmerman, Kristin M},
  title = {A review of proton pump inhibitor use in cystic fibrosis and considerations for deprescribing},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27229}
}
Kostenlos starten →